ArticleRSC advances2019
An erythrocyte membrane coated mimetic nano-platform for chemo-phototherapy and multimodal imaging.
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Cell membrane camouflaged biomimetic nanoparticles: Focusing on tumor theranostics.Materials today. Bio · 2022Article
- Research Progress of Photothermal Nanomaterials in Multimodal Tumor Therapy.Frontiers in oncology · 2022Review
- Phototheranostics Using Erythrocyte-Based Particles.Biomolecules · 2021Review
- Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeutics.Clinical and translational medicine · 2021Review
- Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment.Molecules (Basel, Switzerland) · 2020Review
- The Application of Prussian Blue Nanoparticles in Tumor Diagnosis and Treatment.Sensors (Basel, Switzerland) · 2020Review
- Hybrid red blood cell membrane coated porous silicon nanoparticles functionalized with cancer antigen induce depletion of T cells.RSC advances · 2020Article
- Cell Membrane-Camouflaged Nanocarriers for Cancer Diagnostic and Therapeutic.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor variability and low efficiency associated with conventional chemical drugs provide an impetus to develop drug-carrying systems with targeted accumulation and controllable release behavior. Herein, DOX-loaded Prussian blue (PB) nano-composites are developed after coating with erythrocyte membrane (EM) and modifying with folic acid (FA). In these nano-composites, PB nanoparticles mixture with different shapes were adopted to improve the photothermal performance, which is highly helpful for cancer photothermal ablation and controllable drug release. In addition, the nano-composites were endowed with high biocompatibility, immune evading capacity, pH-/photo-responsive release behavior, and markedly prolonged blood circulation time, which was reflected by a 99.6% cervical tumor growth inhibition value (TGI)
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.